HomeAbout UsContact Us1-800-688-2421
BioWorld
Advanced Search

User ID

Password

Forgot password

Remember my login



New User ?

Products & Services
BIOWORLD TODAY
BIOWORLD INSIGHT
BIOWORLD INTERNATIONAL
BIOTECH RESOURCES
MEDTECH RESOURCES
EXECUTIVE COMPENSATION 2010
BIOFUELS REPORT 2009
MOVING THE NEEDLE 2009
MDD STATE OF THE INDUSTRY
MARKET-LEADING BIOTECH DRUGS
BIOWORLD PERSPECTIVES
AUDIO CONFERENCES
MEDICAL DEVICE DAILY
Untitled Document
BioWorld Stock Index
For the week ending 2/5/10
-1.45

NASDAQ Biotech Index
Close 2/5/10
845.89  -3.13

AMEX Biotech Index
Close 2/5/10
966.86  -6.40
Today's Issue of BioWorld Today

BioWorld Wire, powered by PR Newswire
Biotech news | Pharma news

Monday, February 8, 2010

Today's Headlines

How do you rank among your peers when it comes to compensation packages?

Published by the editors of BioWorld Today, the new BioWorld Executive Compensation Report 2010 provides you with a variety of perspectives on compensation issues by means of key statistics and graphic analyses. This critical examination of executive compensation is a must-have for anyone directly involved in executive compensation within the biotechnology industry!

Carping Over PARPs: Buyout Equals 'Negative' for BioMarin?

With promising early data and a clear Phase III pathway for its GALNS drug in a rare lysosomal storage disorder, BioMarin Pharmaceuticals Inc. said it is no longer in critical need of late-stage assets to fill out its pipeline. (BioWorld Today)

Health Care Reform is Dead; Long Live Health Care Reform!

What did President Obama, backed by one of the largest Democratic majorities in history, accomplish in his first year in the Oval Office? A recent parody on Saturday Night Live summed it up: "When you look at my record, it's very clear what I've done so far. And that is . . . nothing. Nada." (BioWorld Perspectives)

Merus Gets $30M for 'Simple' Antibody Cocktail Platform

Merus BV, which is developing a novel antibody platform, raised €21.7 million (US$30.3 million) in a Series B round and entered a license option agreement with Novartis AG potentially worth more than $200 million in up-front and milestone payments. (BioWorld International)



Upcoming Audio Conferences

Trial Site Insight: Ensure your Trial Master File Will Pass FDA Inspection

Auditing Suppliers and Contractors: Be Ready for Increased FDA Scrutiny

Drug Recalls: Effective Planning for the Inevitable



BioWorld Home   |   About BioWorld   |   Contact Us
Copyright Notices   |   Terms of Use   |   Privacy Statement